guest ::
| Home > Publications database > Macrophage Migration Inhibitory Factor Promotes Thromboinflammation and Predicts Fast Progression of Aortic Stenosis. > print |
| Home > Publications database > Macrophage Migration Inhibitory Factor Promotes Thromboinflammation and Predicts Fast Progression of Aortic Stenosis. > print |
| 001 | 291568 | ||
| 005 | 20240908012536.0 | ||
| 024 | 7 | _ | |a 10.1161/ATVBAHA.124.321000 |2 doi |
| 024 | 7 | _ | |a pmid:38989580 |2 pmid |
| 024 | 7 | _ | |a 0276-5047 |2 ISSN |
| 024 | 7 | _ | |a 1049-8834 |2 ISSN |
| 024 | 7 | _ | |a 1079-5642 |2 ISSN |
| 024 | 7 | _ | |a 1524-4636 |2 ISSN |
| 024 | 7 | _ | |a 2330-9180 |2 ISSN |
| 024 | 7 | _ | |a 2330-9199 |2 ISSN |
| 024 | 7 | _ | |a altmetric:166031733 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01453 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Mueller, Karin Anne Lydia |b 0 |
| 245 | _ | _ | |a Macrophage Migration Inhibitory Factor Promotes Thromboinflammation and Predicts Fast Progression of Aortic Stenosis. |
| 260 | _ | _ | |a Stanford, Calif. |c 2024 |b HighWire |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1725446299_26203 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:D431# / 2024 Sep;44(9):2118-2135 |
| 520 | _ | _ | |a Aortic stenosis (AS) is driven by progressive inflammatory and fibrocalcific processes regulated by circulating inflammatory and valve resident endothelial and interstitial cells. The impact of platelets, platelet-derived mediators, and platelet-monocyte interactions on the acceleration of local valvular inflammation and mineralization is presently unknown.We prospectively enrolled 475 consecutive patients with severe symptomatic AS undergoing aortic valve replacement. Clinical workup included repetitive echocardiography, analysis of platelets, monocytes, chemokine profiling, aortic valve tissue samples for immunohistochemistry, and gene expression analysis.The patients were classified as fast-progressive AS by the median ∆Vmax of 0.45 m/s per year determined by echocardiography. Immunohistological aortic valve analysis revealed enhanced cellularity in fast-progressive AS (slow- versus fast-progressive AS; median [interquartile range], 247 [142.3-504] versus 717.5 [360.5-1234]; P<0.001) with less calcification (calcification area, mm2: 33.74 [27.82-41.86] versus 20.54 [13.52-33.41]; P<0.001). MIF (macrophage migration inhibitory factor)-associated gene expression was significantly enhanced in fast-progressive AS accompanied by significantly elevated MIF plasma levels (mean±SEM; 6877±379.1 versus 9959±749.1; P<0.001), increased platelet activation, and decreased intracellular MIF expression indicating enhanced MIF release upon platelet activation (CD62P, %: median [interquartile range], 16.8 [11.58-23.8] versus 20.55 [12.48-32.28], P=0.005; MIF, %: 4.85 [1.48-9.75] versus 2.3 [0.78-5.9], P<0.001). Regression analysis confirmed that MIF-associated biomarkers are strongly associated with an accelerated course of AS.Our findings suggest a key role for platelet-derived MIF and its interplay with circulating and valve resident monocytes/macrophages in local and systemic thromboinflammation during accelerated AS. MIF-based biomarkers predict an accelerated course of AS and represent a novel pharmacological target to attenuate progression of AS. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a aortic valve stenosis |2 Other |
| 650 | _ | 7 | |a biomarkers |2 Other |
| 650 | _ | 7 | |a blood platelets |2 Other |
| 650 | _ | 7 | |a chemokines |2 Other |
| 650 | _ | 7 | |a inflammation |2 Other |
| 700 | 1 | _ | |a Langnau, Carolin |b 1 |
| 700 | 1 | _ | |a Harm, Tobias |0 0000-0002-6121-2694 |b 2 |
| 700 | 1 | _ | |a Sigle, Manuel |0 0000-0001-8954-4810 |b 3 |
| 700 | 1 | _ | |a Mott, Kristina |0 0000-0002-3223-6857 |b 4 |
| 700 | 1 | _ | |a Droppa, Michal |0 0000-0001-5807-7615 |b 5 |
| 700 | 1 | _ | |a Borst, Oliver |0 0000-0003-4002-4085 |b 6 |
| 700 | 1 | _ | |a Rohlfing, Anne-Katrin |0 0000-0001-5469-3648 |b 7 |
| 700 | 1 | _ | |a Gekeler, Sarah |b 8 |
| 700 | 1 | _ | |a Günter, Manina |0 P:(DE-He78)b676990c2f64e3295740d42e356fb053 |b 9 |u dkfz |
| 700 | 1 | _ | |a Goebel, Nora |0 0000-0002-7692-3480 |b 10 |
| 700 | 1 | _ | |a Franke, Ulrich F W |b 11 |
| 700 | 1 | _ | |a Radwan, Medhat |b 12 |
| 700 | 1 | _ | |a Schlensak, Christian |0 0000-0001-8649-597X |b 13 |
| 700 | 1 | _ | |a Janning, Henrik |0 0000-0002-6497-6972 |b 14 |
| 700 | 1 | _ | |a Scheuermann, Sophia |b 15 |
| 700 | 1 | _ | |a Seitz, Christian M |b 16 |
| 700 | 1 | _ | |a Rath, Dominik |0 0000-0002-5008-2572 |b 17 |
| 700 | 1 | _ | |a Kreisselmeier, Klaus-Peter |b 18 |
| 700 | 1 | _ | |a Castor, Tatsiana |b 19 |
| 700 | 1 | _ | |a Mueller, Iris Irmgard |b 20 |
| 700 | 1 | _ | |a Schulze, Harald |b 21 |
| 700 | 1 | _ | |a Autenrieth, Stella |0 P:(DE-He78)d3dbba28fe1239effd15962787cbc363 |b 22 |e Last author |u dkfz |
| 700 | 1 | _ | |a Gawaz, Meinrad Paul |0 0000-0003-1124-9592 |b 23 |
| 773 | _ | _ | |a 10.1161/ATVBAHA.124.321000 |g p. ATVBAHA.124.321000 |0 PERI:(DE-600)1494427-3 |n 9 |p 2118-2135 |t Arteriosclerosis, thrombosis, and vascular biology |v 44 |y 2024 |x 0276-5047 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:291568 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)b676990c2f64e3295740d42e356fb053 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)d3dbba28fe1239effd15962787cbc363 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ARTERIOSCL THROM VAS : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ARTERIOSCL THROM VAS : 2022 |d 2023-10-21 |
| 920 | 2 | _ | |0 I:(DE-He78)D431-20160331 |k D431 |l Dentritische Zellen bei Infektionen und Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D431-20160331 |k D431 |l Dentritische Zellen bei Infektionen und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D431-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|